Zacks Investment Research upgraded shares of Krystal Biotech (NASDAQ:KRYS) from a sell rating to a hold rating in a report released on Wednesday, Zacks.com reports.

According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “

Other equities analysts also recently issued research reports about the company. HC Wainwright upped their target price on Krystal Biotech from $68.00 to $84.00 and gave the company a buy rating in a report on Friday, January 8th. BidaskClub raised Krystal Biotech from a hold rating to a buy rating in a research note on Wednesday, December 16th. Finally, B. Riley reaffirmed a buy rating and issued a $100.00 price target on shares of Krystal Biotech in a research note on Wednesday, November 11th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $90.00.

KRYS opened at $65.05 on Wednesday. Krystal Biotech has a twelve month low of $33.08 and a twelve month high of $70.07. The company has a 50-day simple moving average of $58.21 and a 200 day simple moving average of $47.59. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -43.95 and a beta of 1.20.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Saturday, November 14th. The company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.02). Sell-side analysts anticipate that Krystal Biotech will post -1.78 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. acquired a new stake in Krystal Biotech in the third quarter valued at $37,000. Liberty One Investment Management LLC increased its position in shares of Krystal Biotech by 103.3% during the third quarter. Liberty One Investment Management LLC now owns 1,037 shares of the company’s stock worth $45,000 after purchasing an additional 527 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Krystal Biotech by 108.2% during the third quarter. BNP Paribas Arbitrage SA now owns 3,223 shares of the company’s stock worth $139,000 after purchasing an additional 1,675 shares in the last quarter. American International Group Inc. increased its position in shares of Krystal Biotech by 17.7% during the second quarter. American International Group Inc. now owns 7,310 shares of the company’s stock worth $303,000 after purchasing an additional 1,097 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Krystal Biotech by 6.4% during the third quarter. The Manufacturers Life Insurance Company now owns 7,783 shares of the company’s stock worth $335,000 after purchasing an additional 465 shares in the last quarter. 71.01% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa.

Featured Article: Net Margin

Get a free copy of the Zacks research report on Krystal Biotech (KRYS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.